CA9 and breast cancer: Targeting CA IX with a sulfonamide inhibitor, SLC-0111, in Phase I clinical trials (NCT02215850) sensitized melanoma cells, breast cancer cells and colorectal cancer cells to chemotherapy [20] and furthermore reduced the enrichment of brain tumor-initiating cells after temozolomide treatment both in vitro and in vivo [21].